Group items tagged

In this comprehensive guide, we will explore what strabismus is, its types, and offer tips for parents on preventing strabismus in infants.

Reckitt has recalled certain catches of Nutramigen LGG stage 1 and stage 2 Hypoallergenic Formula powders over the possible presence of Cronobacter sakazakii. While the products, which are used for special medical purposes for infants, are mainly prescribed, they are also available without a prescription. The precautionary step has been taken after an isolated overseas sample of the product tested positive for Cronobacter sakazakii, said the consumer goods company, adding that a thorough investigation is on. Cronobacter sakazakii is a type of bacteria that can easily survive in dry foods, like powdered infant formula, powdered milk, herbal teas, and starches.

The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees. The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants. Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme. The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

A newly licensed 1mg/ml Omeprazole Powder for Oral Suspension has been developed by Rosemont Pharmaceuticals to meet the special needs of babies from 1 to 12 months old who have gastro-oesophageal reflux disease (GORD). In infants, the symptoms of GORD can be particularly distressing for both the child and parent. Previously, Rosemont Omeprazole Powder for Oral Suspension has been available in 2mg/ml and 4mg/ml strengths. However, the addition of the new 1mg/ml product ensures that the needs of all patient groups with GORD are sufficiently met. The Rosemont range of Omeprazole Powder for Oral Suspension products are the only PPIs (proton pump inhibitors) indicated for use in babies from 1 month to 1 year. Symptoms of GORD in infants are usually resolved by 1 year of age1, so it is key that there is a licensed treatment option available for the 1 to 12 month patient group.

Initial weeks are very hectic for the newborns and their mothers, because in this phase, infants are trying to adapt the new things from the surrounding.

Initial weeks are very hectic for the newborns and their mothers, because in this phase, infants are trying to adapt the new things from the surrounding.

NHS England is set to roll out a new test this week that will help doctors to spot a rare form of eye cancer in babies in the womb. The NHS test developed at Birmingham Women's and Children's NHS Foundation Trust, identifies the risk of developing retinoblastoma in babies that can be monitored and treated sooner - increasing the chance of saving their eyesight and potentially their lives. The new non-invasive test can detect changes in the genes in DNA and is likely to identify around 50 infants with retinoblastoma each year, in the latest example of the NHS harnessing the power of genomics to diagnose and treat patients faster and more effectively. Non-Invasive Prenatal Diagnosis (NIPD) also means parents can be informed early in pregnancy if their child is at risk. "The blood sample test is taken from the mother before birth and tested and analysed for mutations, which can determine with almost 100 per cent accuracy if the baby will develop retinoblastoma," the NHS said.

New data published by the UK Health Security Agency (UKHSA) has revealed that London is potentially at risk of a measles resurgence. UKHSA modelling suggests that, unless MMR vaccination rates improve, London could see a measles outbreak with tens of thousands of cases. "Those who have never received a measles vaccine (MMR) are at risk," said UKHSA. MMR is part of the NHS Routine Childhood Immunisation Programme. Parents whose infants missed out, or anyone of any age unvaccinated, are urged to come forward. Susceptibility is particularly high among 19 to 25 year olds, affected by unfounded stories in the early 2000s ('Wakefield cohorts') and some may still not be fully vaccinated. As part of continued efforts to protect people against getting measles, the NHS is launching a campaign encouraging people to check their vaccination status, with targeted outreach to groups in London.

The Department of Health and Social Care has issued a Serious Shortage Protocol (SSP) in response to a significant ongoing disruption to the supply of Paracetamol 120mg and 240mg suppositories. Effective from Tuesday (Jan 25), SSP015 provides that for every Paracetamol 120mg or 240mg suppository originally prescribed, one Paracetamol 125mg or 250mg suppository must be supplied. SSP015, authorised by the Secretary of State, has been developed by clinicians and provides pharmacists with procedures to follow in providing either of these suitable alternative products to help reduce the number of patients having to return to their prescriber for a replacement prescription. The SSP may be amended or revoked at any time but currently expires on 18 February 2022 - PSNC will update contractors on any changes.